Topical Timolol in Dermatology: Applications and Advances
Timolol, a nonselective β ‐adrenergic receptor blocker approved by the US Food and Drug Administration (FDA) in 1978 for glaucoma treatment, exhibits multiple pharmacological effects including vasoconstriction, promotion of epithelial healing, anti‐inflammatory, and antioxidant properties. Although systemic administration is associated with significant adverse effects, its topical formulations have emerged as a research focus in dermatological therapy due to their superior safety profile and demonstrated efficacy. This article provides a systematic review of the current evidence‐based advancements in the topical application of timolol in dermatology, aiming to offer a theoretical foundation for clinical practice.
Authors
- Luo Yuanyuan (ORCID: https://orcid.org/0009-0007-0226-1801)
- Shan Shan Jing (ORCID: https://orcid.org/0009-0001-0718-280X)
- Wang Yu (ORCID: https://orcid.org/0009-0000-4427-0027)
- Jing Tang (ORCID: https://orcid.org/0009-0001-1232-8009)
- Wang Yue (ORCID: https://orcid.org/0009-0002-2046-8199)
- Mu Yunzu (ORCID: https://orcid.org/0000-0003-4078-5167)
- Tang Shuanglu (ORCID: https://orcid.org/0009-0006-2492-1746)
- Huang Liping (ORCID: https://orcid.org/0009-0008-2389-6539)
- Yu Qiuyue (ORCID: https://orcid.org/0009-0006-6994-3965)
- Feng Yuebi (ORCID: https://orcid.org/0009-0007-9416-3343)
Institutions
- Chengdu Medical College (CN)
- Affiliated Hospital of North Sichuan Medical College (CN)
- First Affiliated Hospital of Chengdu Medical College (CN)
Publication Details
- Journal
- Dermatologic Therapy
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1155/dth/5812080
- Primary Topic
- Glaucoma and retinal disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00